Nivolumab Therapeutic Cheat Sheet
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo …
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo … 
INTRODUCTION
Melanoma accounts for only 1% of all skin cancers but is responsible for most skin cancer-related deaths.1 Acral and mucosal melanoma (AMM) accounts for only 4% of all new melanomas but is associated with poorer prognosis.2 Patients of color are disproportionately affected by AMM. Elucidating the clinical, genetic, and environmental features of AMM can guide advancements in the … 